Vitamin D in standard HCV regimen (PEG-interferon plus ribavirin), its effect on the early virologic response rate: A clinical trial

Vosoghinia, H. and Esmaeilzadeh, A. and Ganji, A. and Hosseini, S. M. R. and Jamehdar, S. A. and Salehi, M. and Bahari, A. and Ghanaei, O. and Sahebari, M. and Rajabzadeh, F. and Ghaffarzadehgan, K. and Goshayeshi, L. (2016) Vitamin D in standard HCV regimen (PEG-interferon plus ribavirin), its effect on the early virologic response rate: A clinical trial. Razavi International Journal of Medicine, 4 (2).

[img] Text

Download (788kB)


Background: Patients chronically infected with the hepatitis C virus (HCV) are more likely to have vitamin D deficiency Recent studies revealed that vitamin D has immunomodulator and antiviral properties and can enhance the effect of interferon on the HCV virus. Objectives: We aimed to assess the influence of vitamin D supplementation on viral response to PegINF/RBV therapy. Patients and Methods: In a randomized-controlled trial 66 patients with HCV (30 with genotype 1or 4 and 36 with genotype 2 or 3) were randomly divided into two groups in gastroenterology clinic: the study group (n = 34) received oral vitamin D supplementation (1600 IU/day) to maintain serum levels > 30 ng/mL besides the routine treatment of 180 µg PegINF-α2a plus oral ribavirin. The control group (n = 32) received the same treatment without vitamin D supplementation. The primary outcome was undetectable HCV-RNA at week 12 of treatment, referred to as complete early viral response (cEVR). Real-time polymerase chain reaction (sensitivity: 10 IU/mL) was used to assess HCV RNA. Serum Vitamin D levels were measured at baseline and weeks 4, 8, 12 and 24 of treatment. Spearman’s correlation showed that baseline vitamin D correlated with the stage of liver fibrosis in both study and control group (P = 0.04, r = 0.57). Results: There were no significant differences in baseline characteristics between two groups except serum AST level. Complete EVR rate at week 12 in the vitamin D group was significantly higher than the controls (100 vs 84.4; P = 0.023) whereas this figure was not significant when genotypes 1 and 4 or 2 and 3 in the test group were compared to those of the control (100 vs 86.7; P = 0.19 and 100 vs 82.4; P = 0.22). Serum vitamin D levels were lowest at baseline (22±15 ng/mL), but increased after 12 weeks of vitamin D therapy to a mean level of 52±38 ng/mL (P = 0.02) in study group. Conclusions: The addition of vitamin D to conventional PegIFN/RBV therapy in HCV patients may significantly improve the viral response. © 2016, Razavi Hospital.

Item Type: Article
Additional Information: Cited By :2 Export Date: 16 February 2020 Correspondence Address: Goshayeshi, L.; Department of Gastroenterology and Hepatology, School of Medicine, Mashhad University of Medical SciencesIran; email:
Uncontrolled Keywords: Early virologic response Hepatitis C Vitamin D alanine aminotransferase aspartate aminotransferase colecalciferol peginterferon alpha2a ribavirin virus RNA adult Article controlled study enzyme linked immunosorbent assay female follow up genotype Hepatitis C virus human infection risk liver fibrosis major clinical study male randomized controlled trial real time polymerase chain reaction reverse transcription polymerase chain reaction treatment outcome virus load vitamin blood level vitamin D deficiency vitamin supplementation
Subjects: QU Biochemistry
Divisions: Mashhad University of Medical Sciences
Depositing User: mr lib4 lib4
Date Deposited: 04 Mar 2020 04:38
Last Modified: 04 Mar 2020 04:38

Actions (login required)

View Item View Item